FATEFate Therapeutics, Inc.

$141M

FY 2012 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+128.2% YoY

Gross Profit

-$9M-349.4% margin

Operating Income

-$14M-507.8% margin

Net Income

-$14M-533.3% margin

EPS (Diluted)

$-1.61

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$14M

Stock-Based Comp.

$155,000

Balance Sheet

Total Assets

$11M

Total Liabilities

$64M

Stockholders' Equity

-$53M

Cash & Equivalents

$9M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$1M	+128.2%
Gross Profit	-$9M	$1M	-897.4%
Operating Income	-$14M	-$13M	-2.0%
Net Income	-$14M	-$13M	-6.0%

FATE FY 2012 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena